Next Article in Journal
Diné (Navajo) Traditional Knowledge Holders’ Perspective of COVID-19
Previous Article in Journal
The Efficacy and Safety of Oral Irrigator on the Control of Dental Plaque and Gingivitis: A Randomized, Single-Blind, Parallel-Group Clinical Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 20
Issue 4
10.3390/ijerph20043725
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Severity and Management of Adverse Drug Reactions Reported by Patients and Healthcare Professionals: A Cross-Sectional Survey

by
Warisara Srisuriyachanchai
1,
Anthony R. Cox
2,
Sirinya Kampichit
3 and
Narumol Jarernsiripornkul
1,*
1
Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand
2
School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
3
Department of Pharmacy Service, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2023, 20(4), 3725; https://doi.org/10.3390/ijerph20043725
Submission received: 11 January 2023 / Revised: 8 February 2023 / Accepted: 15 February 2023 / Published: 20 February 2023
Review Reports Versions Notes

Abstract

:
Adverse drug reaction (ADR) severity levels are mainly rated by healthcare professionals (HCPs), but patient ratings are limited. This study aimed to compare patient-rated and pharmacist-rated ADR severity levels and determined methods employed for ADR management and prevention by patients and HCPs. A cross-sectional survey was conducted in outpatients visiting two hospitals. Patients were asked about ADR experiences using a self-administered questionnaire, and additional information was retrieved from the medical records. In total, 617 out of 5594 patients had experienced ADRs (11.0%), but 419 patients were valid (68.0%). Patients commonly reported that their ADR severity level was moderate (39.4%), whereas pharmacists rated the ADRs as mild (52.5%). There was little agreement between patient-rated and pharmacist-rated ADR severity levels (κ = 0.144; p < 0.001). The major method of ADR management by physicians was drug withdrawal (84.7%), while for patients, it was physician consultation (67.5%). The main methods for ADR prevention by patients and HCPs were carrying an allergy card (37.2%) and recording drug allergy history (51.1%), respectively. A higher level of ADR bothersomeness was associated with higher ADR severity levels (p < 0.001). Patients and HCPs rated ADR severity and used ADR management and prevention methods differently. However, patient rating of ADR severity is a potential signal for severe ADR detection of HCPs.

1. Introduction

Adverse drug reactions (ADRs) are a leading cause of morbidity and mortality [1], and it has been estimated that ADRs are the fourth to sixth highest cause of death in the USA [2]. However, ADR reporting rates are low, with estimated reporting rates between 9 and 15% [2,3,4,5,6]. In one study, the overall incidence of ADRs, including non-serious and serious ADRs, was found to be 10.9% in hospital patients, with 2.1% of ADRs rated as serious and 0.19% as fatal [2]. Although the majority of detected ADRs are mild to moderate [7,8,9,10,11,12], it is the severe ADRs that significantly increase health expenditure [12]. The main independent factors associated with increased severity of ADRs are advanced age, female sex, and concomitant drug use [8,12,13,14,15].
Spontaneous reporting systems (SRSs) are the most commonly employed method of pharmacovigilance utilized by healthcare professionals (HCPs) to report ADRs worldwide. The major limitation of spontaneous reports is under-reporting, with a systematic review estimating that 6% of ADRs are reported [16]. The introduction of patient self-reporting of ADRs has increased reporting rates and is now accepted in many countries [17,18,19,20]. One study found that patient self-reports had the advantage of identifying possible new ADRs that had not previously been reported by HCPs and that the quality of patient reports was equivalent to those provided by HCPs [21]. Several studies have claimed that patients report more extensive detail than reports from HCPs and describe the impact of ADRs on their lives more clearly [18,19,22].
In Thailand, both HCPs and patients can report suspected ADRs to the Health Product Vigilance Center (HPVC), but it is pharmacists that have the main responsibility for ADR monitoring and reporting. Since 2010, patients have been allowed to notify the ADRs to the HPVC. The HPVC has emphasized the importance of ADR monitoring and reporting as a standard drug surveillance method for hospital pharmacists, and hospital pharmacists play an especially important role in the detection, identification, management, and prevention of serious ADRs [23]. The study hospitals mainly used SRS for ADR monitoring, which are regulated by the HPVC as standard drug surveillance methods for hospital pharmacists nationwide.
The severity of ADRs can be measured through standard criteria such as Hartwig’s Severity Assessment Scale, which focuses on objective data and clinically relevant information. In several studies, the incidence of severe ADRs reported by HCPs using the Hartwig Scale ranged from 2% to 10% [9,10,11,12] in comparison to a rate of 20% severe ADRs reported by patients using a visual analog scale (VAS) [8]. The higher incidence of severe ADRs reported by patients reflects the more subjective impact of ADRs on their lives. Most previous studies have rated the severity levels of ADRs by HCPs [9,10,11,12,24] with comparatively limited analysis of patient-rated ADR severity levels [8,25,26,27].
The major ADR management method used by patients [28,29] and HCPs [12,13] is to withdraw the drug suspected of causing the ADR. Other methods are dose management or the use of alternative drugs [30]. HCPs may also use computerized methods to monitor treatment [31] or provide an ADR sticker on the patient tag to manage ADRs [32]. Little is known regarding the comparison between patient- and pharmacist-rated severity levels of ADRs. Therefore, the current study explored patient ADR experiences in order to compare the patient- and pharmacist-rated severities of ADRs, as well as to evaluate ADR management and prevention methods used by patients and HCPs.

2. Materials and Methods

2.1. Study Design and Setting

A cross-sectional study was conducted at outpatient departments of two university hospitals in Northeastern Thailand, namely, Srinagarind Hospital and Queen Sirikit Heart Center of the Northeast, during January to July 2020. Srinagarind Hospital is a teaching hospital, and the Queen Sirikit Heart Center is a tertiary hospital, and both are in the North East of Thailand. Patients who visited both study hospitals were those referred from all community hospitals and general hospitals in the North East region of Thailand. A retrospective study was conducted by exploring the ADRs that patients experienced. Additional information was retrieved from the medical records database including suspected drug, concomitant drugs, patient disease states, signs and symptoms, physical examination, laboratory data, doctors’ and nurses’ notes, and management and prevention of ADRs recorded by HCPs.

2.2. Participants

Eligible participants were patients aged 18 years and over who had most recently experienced ADRs in the past. The study excluded patients who could not read or communicate in the Thai language and patients whose information could not be obtained from the medical records. Sample size was calculated using the Cochrane equation [33] with a 5% margin of error, and 22.4% of the patients reported severe ADRs, with the rate of refusal to participate being similar to that in a previous study at 20% [8,28]. The total number of participants required was at least 400.

2.3. Questionnaire Development

The self-administered questionnaire was developed from our previous studies [27,34,35]. The questionnaire consisted of two sections.
Section 1 consisted of closed questions with a checklist to obtain demographic data. Sex, education level, occupation, income, and information on underlying chronic diseases were collected. An open question was used to obtain age.
Section 2 examined the management and prevention of ADRs and the ADR monitoring process by patients and HCPs. Open-ended questions were used to obtain the name of suspected drugs, indications, and the ADR symptom respondents were most confident in identifying. Participants were also asked to evaluate the severity level of ADRs using a Numerical Rating Scale (NRS) (range 0–10), scored from 0 (no severe) to 10 (most severe). Patients marked “X” on the number 0–10 in NRS line according to their assessment. Closed questions with a checklist were used to obtain information on ADR management and prevention by patients.

2.4. Questionnaire Testing

Three HCPs with proficiency in the field of ADRs validated the content of the developed questionnaire by examining the appropriateness of all questions in accordance with study objectives. The three HCPs included one physician who was regularly involved in ADR monitoring and reporting in Khon Kaen Hospital, as well as two clinical pharmacists who were responsible for ADR monitoring at the study hospitals.
The index of consistency (IOC) was calculated to assess validity. All questions passed content validity testing with IOC > 0.5 for each item. The questionnaire was thereafter adjusted and piloted in 15 patients at outpatient clinics in the study hospitals to evaluate patients’ ability to complete the questionnaire and to obtain any suggestions for improving the questionnaire. The piloted patients were excluded from the main study and final analysis. The final questionnaire was re-adjusted following recommendations from the pilot study and validation testing.

2.5. Questionnaire Distribution and Data Collection

2.5.1. Patient Experience

The final version of the self-administered questionnaire was directly distributed to 419 outpatients by purposive sampling to include patients having experienced ADRs. The participants were over 18 and had the most recently experienced ADRs in the past. The symptoms that patients were most confident in identifying as an ADR were rated their ADR severity levels. The participants were able to complete the questionnaire themselves. The researcher provided assistance by reading the questionnaire to respondents with visual problems but without providing further explanation. The outpatients were recruited while they were waiting to meet physicians at outpatient clinics or to receive the drugs at pharmacy department at two university hospitals. One research pharmacist was responsible for collecting all the patient experience of ADRs in the past to minimize bias of data collection process. Consent forms were given to ask patients’ permission to participate in the study.

2.5.2. Additional Information from Medical Records

Additional information about outpatients reporting ADRs was retrieved from the medical records database. The retrieved data consisted of general information, drug therapy, ADR information, and ADR management and prevention by HCPs. The Hartwig Scale was used to assess the severity of ADRs by a research pharmacist. The Hartwig Scale categorizes ADRs into seven levels of severity. Levels 1 and 2 are mild, levels 3 and 4 are moderate, and levels 5, 6 and 7 are severe. Mild ADRs were defined as self-limiting and able to resolve over time without treatment. Moderate ADRs were defined as those that required treatment or increased length of stay by at least one day. Severe ADRs were defined as those that were life-threatening or caused permanent harm or death [36]. Patients assessed the severity of their suspected ADRs by the ten-point NRS. Patient-reported severity levels of ADR symptoms were classified as mild (score 0–3), moderate (score 4–6), or severe (score 7–10) [37]. Naranjo’s algorithm [38] and the World Health Organization Uppsala Monitoring Centre (WHO-UMC) criteria [39] were subsequently used by a pharmacist for causality assessment of the ADRs patients were most confident in reporting. The Naranjo algorithm has four categories: definite (score > 9), probable (score 5–8), possible (score 1–4), and doubtful (score < 0) [38]. The four WHO criteria categories are certain, probably/likely, possible, and unlikely [39].

2.6. Data Analysis

The questionnaires were analyzed using SPSS for Windows version 26.0. Demographic data, frequencies, and types of ADR were analyzed using descriptive statistics. Pearson’s chi-squared test and Fisher’s exact test were used to compare subgroups for categorical data, and independent-sample t-tests were used for continuous data. The Mann–Whitney U test was used to determine the independence of non-parametric variables. The patient-reported severity level of ADR symptoms were represented in a score range of 0–10 and are presented with either mean ± SD or median and range. The levels of severity of ADRs were divided into binary variables as follows: mild and moderate to severe. Agreement between NRS and the Hartwig Scale was judged to be acceptable on the basis of a Cohen’s kappa (κ). Cohen’s kappa (κ) was interpreted as follows: poor < 0, slight = 0.01–0.20, fair = 0.21–0.40, moderate = 0.41–0.60, substantial = 0.61–0.80, and almost perfect agreement = 0.81–1.00 [40]. Univariate analysis of the factors related to the variables was conducted using Pearson’s chi-squared test. Variables associated with severe ADRs at p-values ≤ 0.25 in the univariate analyses were entered into a multivariate analysis. Multivariate analysis of the factors that related to severity level of ADR symptoms reported by patients was conducted using logistic regression. Results with p-values less than 0.05 were considered statistically significant. Potential sources of bias might be recall bias, selection bias, and under-representation of populations. As underlying diseases and advanced age might be confounding variables [7,41], these variables were subgrouped for data analysis.

3. Results

3.1. Response Rate

A total of 5594 patients were approached and asked about their experience of suspected medicine-related symptoms, and 617 claimed that they had experienced ADRs (11.0%). All 617 patients were invited to participate in the study by the research pharmacist, and 419 questionnaires were completed and analyzed (response rate 68.0%). The main reasons given for refusal to participate in the study were it not being convenient (n = 63, 31.8%) and forgetting details of experienced ADRs (n = 44, 22.2%). Seven participants were excluded due to incomplete data (3.5%), 73 because drug allergy histories were not found in the medical records (36.9%), and 11 because their medical records could not be assessed (5.6%). Of the total 419 participants, 298 were collected from Srinagarind Hospital (71.1%) and 121 were from Queen Sirikit Heart Center of the Northeast, Thailand (28.9%).

3.2. Demographic Data

The majority of respondents were female (n = 278, 66.3%), with an average age of 59.2 ± 14.13 years (range 20–89). Half of the patients were aged more than 60 years (n = 228, 54.4%), and education levels were secondary school and lower (n = 223, 53.2%) or a bachelor’s degree and higher (n = 189, 45.1%). About one-third of respondents were employed in government or state enterprises (n = 157, 37.5%). The majority of patients had underlying diseases (n = 372, 88.8%). Half of the patients reported that their recent ADRs occurred within the last 5 years (n = 228, 54.5%). Half of the patients reported that the suspected ADRs lasted less than 24 h (n = 238, 56.7%), and almost two-thirds of respondents reported ADR duration of less than 3 days (n = 256, 61.1%) (Table 1).
Of the 419 respondents, the top three reported ADRs classified by systemic organ class (SOC) were skin tissue disorders (n = 299, 71.4%) including rash (n = 203, 48.4%), respiratory system disorders (n = 29, 6.9%) including dyspnea (n = 29, 6.9%), and gastrointestinal disorders (n = 18, 4.3%) including nausea/vomiting (n = 9, 2.1%). The most common suspected drugs classified by anatomical therapeutic chemical (ATC) with their reported ADRs were penicillin (n = 73)-induced rash, sulfamethoxazole and trimethoprim (n = 33)-induced rash, and enalapril (n = 22)-induced dry cough. The severity of the ADRs experienced by patients were reported as mild in 24.1% of cases, moderate in 39.4% of cases, and severe in 36.5% of cases. HCPs rated the severity of ADRs as mild in 52.5% of cases, moderate in 40.8% of cases, and severe in 6.7% of cases. According to the Naranjo algorithm, the number of definite ADRs was 6 (1.4%), while 155 were classified as probable (37.0%) and 257 as possible (61.3%), with 1 suspected ADR (0.2%) classified as a doubtful or false ADR. According to the WHO criteria, the number of suspected ADRs classified as certain was 9 (2.1%), with 136 probable (32.5%) and 273 possible (65.2%). One suspected ADR (0.2%) was also classified as unlikely or false according to the WHO criteria. Thus, 418 out of 419 (99.8%) of the suspected ADRs were classified as true ADRs according to both methods.

3.3. Agreement between Severity Assessment Tools

There was slight agreement (percentage of positive agreement = 41.1, κ = 0.144) between the NRS patient-rated and the Hartwig Scale pharmacist-rated severity levels of ADRs (Table 2).

3.4. ADR Management by Patients and Physicians

The top three methods of ADR management by patients were immediate physician consult (67.5%), drug withdrawal (45.4%), and continue drug in same dose (9.9%). A significant increase in the proportion of patients who reported immediate physician consult (85.4%, p < 0.001) was found for patients with ADRs rated as moderate to severe by the Hartwig Scale. For patients with ADRs rated as moderate to severe by NRS, there was a significant increase in the proportion of patients reporting immediate physician consult (71.5%, p = 0.002) (Table 3).
The major method of ADR management by physicians was drug withdrawal (84.7%). For patients who rated the severity level of ADRs by NRS, there were no significant differences for all methods of ADR management. Patients with ADRs rated as moderate to severe by the Hartwig Scale were found to have a higher proportion managed by drug withdrawal (90.4%), followed by giving another drug for treating ADRs (53.4%). A significant difference in the physicians’ ADR management method was only seen for giving another drug for treating ADRs (p < 0.001) (Table 3).

3.5. ADR Prevention by Patients and HCPs

The carrying of allergy cards was the only method that patients used for prevention of their ADRs (n = 156, 37.2%). Regarding ADR prevention by HCPs, 214 (51.1%) patient ADRs were recorded in the medical records or electronic records, 173 (41.3%) patients had been given an allergy card, but only 55 (13.1%) had a sticker attached to their medical records. Patients with ADRs rated as moderate to severe by NRS were found to have a higher proportion that received an allergy card (n = 140, 44.0%) and attached a sticker to medical records (n = 43, 13.5%)), but a significant difference was only seen for received allergy cards (p = 0.044). Patients with ADRs rated as moderate to severe by the Hartwig Scale were found to have a higher proportion of all methods of ADR prevention, and significant differences were seen in the medical records or electronic records (p = 0.003), received allergy cards (p < 0.001), and attached stickers to medical records (p = 0.022) (Table 4).

3.6. Reported ADRs and Suspected Drugs in Patients with Severe ADRs (Rated by NRS)

The most common reported ADRs that resulted in immediate physician consultations by patients and drug withdrawal by HCPs were rash, dyspnea, and angioedema, which were similar for all methods of ADR prevention by patients and HCPs. For ADRs that resulted in a decrease in the dose by HCPs, the most commonly reported ADRs were dependent on the pharmacological effect of the drug such as ankle edema or bleeding. The main suspected drugs that were identified by most methods of ADR management and prevention were antibiotics and NSAIDs. ADRs resulting from cardiovascular drugs such as enalapril, amlodipine, and statins were managed by decreasing dose or changing to an alternative drug (Table 5).

3.7. Factors Related to Severity Levels of ADR Symptoms

The univariate analysis of the factors affecting the severity levels of ADRs that were rated by NRS showed that sex (p < 0.001), age (p = 0.085), and increased levels of ADR bothersomeness (p < 0.001) were significantly associated with higher levels of ADR severity. The follow-up multiple logistic regression analysis showed that the factors independently associated with severity levels of ADRs were a medium level of ADR bothersomeness (OR 3.678; 95% CI 2.029, 6.666; p < 0.001) and a high level of ADR bothersomeness (OR 26.211; 95% CI 9.077, 75.658; p < 0.001) (Table 6).
The univariate analysis of the factors affecting the severity levels of ADRs that were rated by the Hartwig’s Severity Assessment Scale showed that sex (p = 0.063), education level (p = 0.166), underlying diseases (p = 0.033), onset of ADRs (p = 0.092), duration of ADRs (p = 0.155), and increased levels of ADR bothersomeness (p < 0.001) were significantly associated with levels of ADR severity. The follow-up multiple logistic regression analysis showed that the factors independently associated with higher severity levels of ADRs were medium level of ADR bothersomeness (OR 2.300; 95% CI 1.359, 3.892; p = 0.002) and high level of ADR bothersomeness (OR 3.951; 95% CI 2.372, 6.581; p < 0.001). The factors independently associated with lower severity levels of ADRs were duration of ADRs between 4 day and 4 weeks (OR 0.441; 95% CI 0.256, 0.758; p = 0.003) and duration of ADRs more than 1 month (OR 0.388; 95% CI 0.180, 0.834; p = 0.015) (Table 6).

4. Discussion

The percentages of male and female individuals participating in this study were 33.7% and 66.3%, respectively, which is similar to similar studies undertaken in Thai populations [8,35]. Moreover, in line with previous studies, the most frequently reported ADRs as classified by systemic organ class (SOC) were skin tissue disorders [28,35,42], and the most common drug group suspected of causing ADRs was anti-infectives [12,28,42,43]. Previous studies have provided limited data to compare severity rating scales between patients and HCPs [8,9,10,11,12,24,25,26]. The major strength of our study is the rating of ADR severity levels by both patients and HCPs. Patients’ ADR reports have been shown to be more extensive in the amount of detail provided about reactions and more often describe the effects of ADRs on their’ lives [22]. On the other hand, ADR reports from HCPs are considered to provide more objective data and are based on clinically related information [19].
Patients usually report possible connections between suspected drugs and their symptoms, and they tend to report common, less-serious symptoms that affect their daily life [7,8,22,27,28,44]. In contrast, HCPs often report more serious ADRs [45]. This study showed that patients frequently rated ADRs as moderate to severe, whereas HCPs frequently rated ADRs as mild. A previous study found that a low number of reported symptoms and a high level of confidence were two factors that were related to accuracy in ADR identification [35]. Moreover, a temporal relationship between the onset of symptoms and the taking of a drug was the main issue that patients used to confirm a suspected ADR [7,18]. This study showed that the NRS patient-rated and the Hartwig Scale pharmacist-rated severity levels of ADRs were not a perfect match. NRS patient ratings provided a high proportion of moderate-to-severe ADRs, but the Hartwig Scale pharmacist ratings provided high proportion of mild-to-moderate ADRs. Patient ratings showed a slight but significant agreement (κ = 0.144) with the Hartwig Scale pharmacist ratings. These findings indicate that patients and pharmacists rate the severity levels of ADRs differently. Nevertheless, patients should still notify the ADR severity to pharmacists for further assessment.
Interestingly, some patients (12.6%) rated ADR severity level as severe, but HCPs rated it as mild, which may affect the patients’ adherence to treatment [46]. On the other hand, for ADRs that patients rated as mild, this may lead to patients not reporting their ADR symptoms to HCPs, with potentially serious consequences of severe ADRs. Increasing patient awareness of ADR monitoring, including paying attention to ADR information or ADR bothersomeness, may reduce the chance of harm for severe ADRs. Improving patients’ awareness in the observation of ADR symptoms or laboratory data, ADR knowledge and increase communication to HCPs should be promoted. Despite differences in ADR severity level assessments by patients and HCPs, there are potential benefits from sharing of both assessments. HCPs tend to assess the severity level of ADRs on the basis of objective data and clinically relevant information, whereas patients assess the severity of ADRs from subjective data about how the symptoms affect their daily life [22]. Sharing assessments of ADR severity levels between patients and HCPs could have potential benefits for early detection of severe ADRs.
The current study found that the main method patients used for management of ADRs was to directly consult with a physician, but previous studies have shown that patients stop taking their medication by themselves after experiencing an ADR [28,29]. The most frequent ADR management method applied by HCPs was drug withdrawal [12,13,47], which is a method considered suitable to manage severe ADRs [47]. Other methods used by HCPs such as dose reductions were used in response to ADRs resulting from the drugs pharmacological action. The most frequent ADR management in non-serious ADRs were pharmacologic and non-pharmacologic treatment or dose management [30]. The ADR severity levels were related to the different methods used for ADR management.
The most frequent ADR prevention method reported by HCPs was noting the ADR in the medical records or electronic health records, in line with other studies using computer alerts [31,48]. Improvements in hospital database systems and providing support to physicians to use them may have a beneficial impact on the safety of medical treatment [48]. In addition to annotating electronic health records, providing an allergy card or attaching a sticker to the medical records were the major methods used to prevent and minimize ADRs. The major ADR prevention method reported by patients was carrying an allergy card, one of the most effective methods used in one study [32].
In this study, univariate analysis showed that sex, age, and level of ADR bothersomeness were the factors related to severity level of ADRs (as rated by NRS). Female patients seem to be at greater risk of developing severe ADRs [12,49], as are patients of advanced age [8,12]. Patients aged 45–60 years have a 1.97-fold greater risk of developing severe ADRs compared to the rest of the population, and a previous study showed that patients aged 30–50 years experience more severe ADRs [8]. However, the multivariate analysis found that it was only higher levels of ADR bothersomeness that were associated with ADR severity, which is similar to the findings of a previous study [8]. Moreover, univariate analysis showed that sex, duration of ADR symptoms, and level of ADR bothersomeness were the factors related to severity level of ADRs (rated by the Hartwig’s Severity Assessment Scale). However, ADR severity levels or seriousness was evaluated by physicians on the basis of life threatening patterns of ADRs.
Currently, information on patient-rated and pharmacist-rated severity of ADRs has been limited. The strengths of the study were that this is the first study to compare patient-rated and pharmacist-rated severity levels of ADRs and the pharmacist-rated ADR severity levels made by one research pharmacist using standard criteria to minimize the bias of the assessment. The current study has some limitations. Incomplete data retrieving from the medical records database led to a number of invalid participants for data analysis. However, the study was conducted in the northeastern region of Thailand, and hence the findings may not be generalized to all patients and HCPs in Thailand. Moreover, the gathered findings were obtained from a self-administered questionnaire, which may be subject to recall and social desirability biases.

5. Conclusions

Patients and HCP ratings of ADR severity differ with practical consequences for reporting and management of ADRs. Patients were more likely to rate ADR severity as severe ADRs due to the effects on their daily life, but HCPs tend to assess ADR severity levels using more clinically relevant information. Higher levels of ADR bothersomeness were significantly associated with severe ADRs when rated by patients and HCPs. Methods of ADR management and prevention varied between severity levels. However, patient self-rating of ADR severity may support ADR monitoring by HCPs. Patient- and HCP-rated ADR severity level should be implemented in practices.

Author Contributions

Conceptualization, N.J. and A.R.C.; methodology, N.J., A.R.C. and W.S.; software, W.S. and N.J.; validation, W.S., N.J. and S.K.; formal analysis, W.S. and N.J.; investigation, N.J. and A.R.C.; resources, N.J.; data curation, W.S. and S.K.; writing—original draft preparation, W.S.; writing—review and editing, N.J. and A.R.C.; visualization, W.S. and N.J.; supervision, N.J. and A.R.C.; project administration, N.J.; funding acquisition, N.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Royal Golden Jubilee Ph.D. Programme Scholarship (Grant No. PHD/0161/2561) of the Thailand Research Fund.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Khon Kaen University Ethics Committee for Human Research (Number HE621444 on 16 December 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data used in this study are available upon request from the corresponding author.

Acknowledgments

We thank the Royal Golden Jubilee Ph.D. Programme of the Thailand Research Fund for supporting this research (Grant No. PHD/0161/2561). Special thanks are expressed to all patients who completed questionnaires and to all staff who provided help in data collection at Srinagarind hospital and Queen Sirikit Heart Center of the Northeast.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. World Health Organization. Safety of Medicines—A Guide to Detecting and Reporting Adverse Drug Reactions-Why Health Professionals Need to Take Action. Available online: https://apps.who.int/iris/handle/10665/67378 (accessed on 31 January 2023).
  2. Lazarou, J.; Pomeranz, B.H.; Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998, 279, 1200–1205. [Google Scholar] [CrossRef] [PubMed]
  3. Chan, S.L.; Ang, X.; Sani, L.L.; Ng, H.Y.; Winther, M.D.; Liu, J.J.; Brunham, L.R.; Chan, A. Prevalence and characteristics of adverse drug reactions at admission to hospital: A prospective observational study. Br. J. Clin. Pharmacol. 2016, 82, 1636–1646. [Google Scholar] [CrossRef] [Green Version]
  4. Impicciatore, P.; Choonara, I.; Clarkson, A.; Provasi, D.; Pandolfini, C.; Bonati, M. Incidence of adverse drug reactions in paediatric in/out-patients: A systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol. 2001, 52, 77–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Prashanthi, B.; Modi, H.; Kalagara, D. Adverse drug reactions (ADR’S) monitoring at tertiary care Hospital. J. Drug Deliv. Ther. 2019, 9, 195–198. [Google Scholar] [CrossRef] [Green Version]
  6. Rebelo Gomes, E.; Fonseca, J.; Araujo, L.; Demoly, P. Drug allergy claims in children: From self-reporting to confirmed diagnosis. Clin. Exp. Allergy 2008, 38, 191–198. [Google Scholar] [CrossRef] [PubMed]
  7. Jarernsiripornkul, N.; Patsuree, A.; Krska, J. Public confidence in ADR identification and their views on ADRreporting: Mixed methods study. Eur. J. Clin. Pharmacol. 2017, 73, 223–231. [Google Scholar] [CrossRef] [PubMed]
  8. Kampichit, S.; Pratipanawatr, T.; Jarernsiripornkul, N. Severity of adverse drug reactions by patient self-reporting. Srinagarind. Med. J. 2018, 33, 113–121. [Google Scholar]
  9. Sundaran, S.; Udayan, A.; Hareendranath, K.; Eliyas, B.; Ganesan, B.; Hassan, A.; Subash, R.; Palakkal, V.; Salahudeen, M.S. Study on the classification, causality, preventability and severity of adverse drug reaction using spontaneous reporting system in hospitalized patients. Pharmacy 2018, 6, 108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Petrova, G.; Stoimenova, A.; Dimitrova, M.; Kamusheva, M.; Petrova, D.; Georgiev, O. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. SAGE Open Med. 2017, 5, 2050312117690404. [Google Scholar] [CrossRef] [Green Version]
  11. Prajapati, K.; Desai, M.; Shah, S.; Panchal, J.; Kapadia, J.; Dikshit, R. An analysis of serious adverse drug reactions at a tertiary care teaching hospital. Perspect. Clin. Res. 2016, 7, 181–186. [Google Scholar] [CrossRef]
  12. Geer, M.I.; Koul, P.A.; Tanki, S.A.; Shah, M.Y. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. J. Pharmacol. Toxicol. Methods 2016, 81, 323–334. [Google Scholar] [CrossRef] [PubMed]
  13. Bhabhor, P.H.; Patel, T.K.; Vahora, R.; Patel, P.B.; Desai, N. Adverse drug reactions in a tertiary care teaching hospital in India: Analysis of spontaneously reported cases. Int. J. Basic. Clin. Pharmacol. 2014, 3, 8. [Google Scholar] [CrossRef] [Green Version]
  14. Onder, G.; Pedone, C.; Landi, F.; Cesari, M.; Della Vedova, C.; Bernabei, R.; Gambassi, G. Adverse drug reactions as cause of hospital admissions: Results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J. Am. Geriatr. Soc. 2002, 50, 1962–1968. [Google Scholar] [CrossRef]
  15. Mannesse, C.K.; Derkx, F.H.; de Ridder, M.A.; Man in’t Veld, A.J.; van der Cammen, T.J. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 2000, 29, 35–39. [Google Scholar] [CrossRef] [Green Version]
  16. Hazell, L.; Shakir, S.A.W. Under-reporting of adverse drug reactions. Drug Saf. 2006, 29, 385–396. [Google Scholar] [CrossRef]
  17. Aagaard, L.; Nielsen, L.H.; Hansen, E.H. Consumer Reporting of Adverse Drug Reactions. Drug Saf. 2009, 32, 1067–1074. [Google Scholar] [CrossRef]
  18. Avery, A.J.; Anderson, C.; Bond, C.; Fortnum, H.; Gifford, A.; Hannaford, P.; Hazell, L.; Krska, J.; Lee, A.; McLernon, D.; et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: Literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol. Assess. 2011, 15, 1–234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. de Langen, J.; van Hunsel, F.; Passier, A.; den Berg, L.d.J.-v.; van Grootheest, K. Adverse drug reaction reporting by patients in the Netherlands three years of experience. Drug Saf. 2008, 31, 515–524. [Google Scholar] [CrossRef]
  20. Inch, J.; Watson, M.C.; Anakwe-Umeh, S.; Collaboration, Y.C.S. Patient versus healthcare professional spontaneous adverse drug reaction reporting. Drug Saf. 2012, 35, 807–818. [Google Scholar] [CrossRef] [PubMed]
  21. Blenkinsopp, A.; Wilkie, P.; Wang, M.; Routledge, P.A. Patient reporting of suspected adverse drug reactions: A review of published literature and international experience. Br. J. Clin. Pharmacol. 2007, 63, 148–156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Rolfes, L.; van Hunsel, F.; Wilkes, S.; van Grootheest, K.; van Puijenbroek, E. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information. Pharmacoepidemiol. Drug Saf. 2015, 24, 152–158. [Google Scholar] [CrossRef] [PubMed]
  23. Lan, T.; Wang, H.; Li, X.; Yin, H.; Shao, D.; Jiang, Y.; Yu, Q. The effect of clinical pharmacists’ intervention in adverse drug reaction reporting: A retrospective analysis with a 9-year interrupted time series. BMC Health Serv. Res. 2022, 22, 925. [Google Scholar] [CrossRef]
  24. Suh, D.-C.; Woodall, B.S.; Shin, S.-K.; Santis, E.R.H.-D. Clinical and Economic Impact of Adverse Drug Reactions in Hospitalized Patients. Ann. Pharmacother. 2000, 34, 1373–1379. [Google Scholar] [CrossRef]
  25. Avery, C.W.; Ibelle, B.; Allison, B.; Mandell, N. Systematic errors in the evaluation of side effects. Am. J. Psychiatr. 1967, 123, 875–878. [Google Scholar] [CrossRef] [PubMed]
  26. Rief, W.; Barsky, A.J.; Glombiewski, J.A.; Nestoriuc, Y.; Glaesmer, H.; Braehler, E. Assessing general side effects in clinical trials: Reference data from the general population. Pharmacoepidemiol. Drug Saf. 2011, 20, 405–415. [Google Scholar] [CrossRef]
  27. Jarernsiripornkul, N.; Patsuree, A.; Krska, J. Survey of patients’ experiences and their certainty of suspected adverse drug reactions. Int. J. Clin. Pharm. 2015, 37, 168–174. [Google Scholar] [CrossRef]
  28. Patsuree, A.; Krska, J.; Jarernsiripornkul, N. Experiences relating to adverse drug reactions in the community: A cross-sectional survey among patients and the general public in Thailand. Expert Opin. Drug Saf. 2016, 15, 287–295. [Google Scholar] [CrossRef] [PubMed]
  29. Sabblah, G.T.; Darko, D.M.; Mogtari, H.; Härmark, L.; van Puijenbroek, E. Patients’ perspectives on adverse drug reaction reporting in a developing country: A case study from Ghana. Drug Saf. 2017, 40, 911–921. [Google Scholar] [CrossRef]
  30. Srinivas, S.; Stein, D.; Teltsch, D.Y.; Tao, S.; Cisar, L.; Ramaswamy, K. Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma. J. Oncol. Pharm. Pract. 2018, 24, 574–583. [Google Scholar] [CrossRef]
  31. Pestotnik, S.L.; Classen, D.C.; Evans, R.S.; Stevens, L.E.; Burke, J.P. Prospective Surveillance of Imipenem/Cilastatin Use and Associated Seizures Using a Hospital Information System. Ann. Pharmacother. 1993, 27, 497–501. [Google Scholar] [CrossRef]
  32. Chaikoolvatana, A.; Chanakit, T.; Juengrakpong, A. The evaluation of a recurrent Adverse Drug Reaction Prevention Program in the north-east region of Thailand. J. Med. Assoc. Thail. 2006, 89, 699–705. [Google Scholar]
  33. Cochran, W.G. Sampling Techniques, 3rd ed.; John Wiley & Sons: New York, NY, USA, 1977. [Google Scholar]
  34. Chaipichit, N.; Krska, J.; Pratipanawatr, T.; Jarernsiripornkul, N. Statin adverse effects: Patients’ experiences and laboratory monitoring of muscle and liver injuries. Int. J. Clin. Pharm. 2015, 37, 355–364. [Google Scholar] [CrossRef] [PubMed]
  35. Kampichit, S.; Pratipanawatr, T.; Jarernsiripornkul, N. Confidence and accuracy in identification of adverse drug reactions reported by outpatients. Int. J. Clin. Pharm. 2018, 40, 1559–1567. [Google Scholar] [CrossRef] [PubMed]
  36. Hartwig, S.C.; Siegel, J.; Schneider, P.J. Preventability and severity assessment in reporting adverse drug reactions. Am. J. Health Syst. Pharm. 1992, 49, 2229–2232. [Google Scholar] [CrossRef]
  37. Haefeli, M.; Elfering, A. Pain assessment. Eur. Spine J. 2006, 15 (Suppl. S1), S17–S24. [Google Scholar] [CrossRef]
  38. Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30, 239–245. [Google Scholar] [CrossRef]
  39. The Uppsala Monitoring Centre. The Use of the WHO-UMC System for Standardised Case Causality Assessment. Available online: https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf (accessed on 31 January 2023).
  40. Viera, A.J.; Garrett, J.M. Understanding interobserver agreement: The kappa statistic. Fam. Med. 2005, 37, 360–363. [Google Scholar]
  41. Rhodes, S.; Greene, N.R.; Naveh-Benjamin, M. Age-related differences in recall and recognition: A meta-analysis. Psychon. Bull. Rev. 2019, 26, 1529–1547. [Google Scholar] [CrossRef] [Green Version]
  42. Giardina, C.; Cutroneo, P.M.; Mocciaro, E.; Russo, G.T.; Mandraffino, G.; Basile, G.; Rapisarda, F.; Ferrara, R.; Spina, E.; Arcoraci, V. Adverse drug reactions in hospitalized patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Front. Pharmacol. 2018, 9, 350. [Google Scholar] [CrossRef]
  43. Kamalraj, R.; Revathy, J.; Muthukumar, V.A.; Murugan, M.; Ramanakumar, K.P.V. Incidence, severity and financial burden associated with suspected unexpected serious adverse reactions (SUSARs) that arise in clinical trials. Asian J. Pharm. Clin. Res. 2012, 5, 98–101. [Google Scholar]
  44. Golomb, B.A.; McGraw, J.J.; Evans, M.A.; Dimsdale, J.E. Physician response to patient reports of adverse drug effects. Drug Saf. 2007, 30, 669–675. [Google Scholar] [CrossRef] [PubMed]
  45. Matsuda, S.; Aoki, K.; Kawamata, T.; Kimotsuki, T.; Kobayashi, T.; Kuriki, H.; Nakayama, T.; Okugawa, S.; Sugimura, Y.; Tomita, M.; et al. Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS ONE 2015, 10, e0126413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Leporini, C.; De Sarro, G.; Russo, E. Adherence to therapy and adverse drug reactions: Is there a link? Expert Opin. Drug Saf. 2014, 13 (Suppl. S1), S41–S55. [Google Scholar] [CrossRef] [PubMed]
  47. Costa, M.J.; Herdeiro, M.T.; Polonia, J.J.; Ribeiro-vaz, I.; Botelho, C.; Castro, E.; Cernadas, J. Type B adverse drug reactions reported by an immunoallergology department. Pharm. Pract. 2018, 16, 1070. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Raschke, R.A.; Gollihare, B.; Wunderlich, T.A.; Guidry, J.R.; Leibowitz, A.I.; Peirce, J.C.; Lemelson, L.; Heisler, M.A.; Susong, C. A computer alert system to prevent injury from adverse drug events: Development and evaluation in a community teaching hospital. JAMA 1998, 280, 1317–1320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Rademaker, M. Do Women Have More Adverse Drug Reactions? Am. J. Clin. Dermatol. 2001, 2, 349–351. [Google Scholar] [CrossRef]
Table
Table 1. Demographic characteristics of respondents.
Table 1. Demographic characteristics of respondents.
CharacteristicsNumber of Patients; N (%)p-Value a
Mild c
(n = 101)		Moderate to Severe c
(n = 318)		Total
(n = 419)
Sex
 Male51 (50.5)90 (28.3)141 (33.7)<0.001 *
 Female50 (49.5)228 (71.7)278 (66.3)
Age (years)
  18–4415 (14.9)51 (16.0)66 (15.8)0.085
  45–6022 (21.8)103 (32.4)125 (29.8)
  >6064 (63.4)164 (51.6)228 (54.4)
 Mean ± SD60.0 ± 13.3658.9 ± 14.3759.2 ± 14.130.434 b
 Median (range)64 (24–85)61 (20–89)62 (20–89)
Occupation
 No carrer23 (22.8)68 (21.4)91 (21.7)0.397
 Farmer + worker20 (19.8)89 (28.0)109 (26.0)
 Government + state enterprises43 (42.6)114 (35.8)157 (37.5)
 Own bussiness15 (14.9)47 (14.8)62 (14.8)
Education level
 Secondary school and lower52 (51.5)171 (53.8)223 (53.2)0.540
 Bachelor’s degree and higher49 (48.5)140 (44.0)189 (45.1)
 Unknown7 (1.7)
Underlying diseases
 Yes92 (91.1)280 (88.1)372 (88.8)0.484
 No9 (8.9)36 (11.3)45 (10.7)
 Unknown2 (0.5)
When most recent ADRs occurred 0.101
 Within the past week7 (6.9)15 (4.7)22 (5.3)
 1–4 weeks ago4 (4.0)12 (3.8)16 (3.8)
 1–6 months ago16 (15.8)27 (8.5)43 (10.3)
 6–12 months ago5 (5.0)19 (6.0)24 (5.7)
 1–5 years ago20 (19.8)103 (32.4)123 (29.3)
 More than 5 years ago47 (46.5)140 (44.0)187 (44.6)
 Unknown4 (1.0)
Onset of ADRs
 Acute (<1 h)21 (20.8)81 (25.5)102 (24.3)0.630
 Subacute (1–24 h)35 (34.7)101 (31.8)136 (32.4)
 Latent (>24 h)44 (43.6)134 (42.1)178 (42.5)
 Unknown3 (0.7)
Duration of ADRs
 <1–24 h37 (36.6)107 (33.6)144 (34.4)0.719
 1–3 days27 (26.7)85 (26.7)112 (26.7)
 4 days–4 weeks22 (21.8)87 (27.4)109 (26.0)
 >1 month8 (7.9)32 (10.1)40 (9.5)
 Unknown14 (3.3)
Bothersome ADRs
 Low57 (56.4)85 (26.7)142 (33.9)<0.001 *
 Medium13 (12.9)86 (27.0)99 (23.6)
 High4 (4.0)132 (41.5)136 (32.5)
a Pearson’s chi-squared test, b Mann–Whitney U test, c ADR severity level were rated by the Numerical Rating Scale (NRS), * the level of significant difference <0.05.
Table
Table 2. Agreement of severity assessment between the Numerical Rating Scale and Hartwig’s Severity Assessment Scale (n = 419).
Table 2. Agreement of severity assessment between the Numerical Rating Scale and Hartwig’s Severity Assessment Scale (n = 419).
ADR Severity LevelNumerical Rating Scale
MildModerateSevereTotal
Hartwig’s Severity
Assessment Scale		Mild75 (34.1)92 (41.8)53 (2.41)220 (100.0)
Moderate26 (15.2)71 (41.5)74 (43.3)171 (100.0)
Severe0 (0.0)2 (7.1)26 (92.9)28 (100.0)
Total101 (24.1)165 (39.4)153 (36.5)419 (100.0)
Percentage of positive agreement172 (41.1)
Kappa0.144
p-value<0.001
Table
Table 3. Relationship between management of ADRs by patients and HCPs in relation to severity level by the Numerical Rating Scale and Hartwig’s Severity Assessment Scale.
Table 3. Relationship between management of ADRs by patients and HCPs in relation to severity level by the Numerical Rating Scale and Hartwig’s Severity Assessment Scale.
MethodsManagement by Patients; N (%)
NRS a by PatientsHartwig b by Pharmacist
Mild
(n = 100)		Moderate to Severe
(n = 316)		Total #
(n = 416)		p-Value cMild
(n = 218)		Moderate to Severe
(n = 198)		Total
(n=416)		p-Value c
  • Drug withdrawal
48 (48.0)141 (44.6)189 (45.4)0.554117 (53.7)72 (36.4)189 (45.4)<0.001 *
  • Continue drug (same dose)
11 (11.0)30 (9.5)41 (9.9)0.66027 (12.4)14 (7.1)41 (9.9)0.069
  • Use another drug for treating ADRs
1 (1.0)3 (0.9)4 (1.0)1.000 d2 (0.9)2 (1.0)4 (1.0)1.000 d
  • Consult with community pharmacist
8 (8.0)8 (2.5)16 (3.8)0.019 d9 (4.1)7 (3.5)16 (3.8)0.753
  • Searching for more information
6 (6.0)10 (3.2)16 (3.8)0.231 d13 (6.0)3 (1.5)16 (3.8)0.018 *
  • Immediate physician consultation
55 (55.0)226 (71.5)281 (67.5)0.002 *112 (51.4)169 (85.4)281 (67.5)<0.001 *
MethodsManagement by Physicians; N (%)
NRS a by PatientsHartwig b by Pharmacist
Mild
(n = 34)		Moderate to Severe
(n = 110)		Total $
(n = 144)		p-Value cMild
(n = 71)		Moderate to Severe
(n=73)		Total
(n = 144)		p-Value c
  • Drug withdrawal
29 (85.3)93 (84.5)122 (84.7)0.91656 (78.9)66 (90.4)122 (84.7)0.054
  • Continue drug (decrease dose)
3 (8.8)12 (10.9)15 (10.4)1.000 d11 (15.5)4 (5.5)15 (10.4)0.049 *
  • Continue drug (same dose)
2 (5.9)7 (6.4)9 (6.3)1.000 d6 (8.5)3 (4.1)9 (6.3)0.323 d
  • Change to alternative drug
12 (35.3)40 (36.4)52 (36.1)0.91037 (52.1)15 (20.5)52 (36.1)<0.001 *
  • Giving another drug for treating ADRs
11 (32.4)30 (27.3)41 (28.5)0.5662 (2.8)39 (53.4)41 (28.5)<0.001 *
a NRS: Numerical Rating Scale: mild (0–3), moderate (4–6), and severe (7–10). b Hartwig: Hartwig’s Severity Assessment Scale: mild (1–2), moderate (3–4), and severe (5–7). c Pearson’s chi-squared test, d Fisher’s exact test, * the level of significant difference < 0.05. # Patients did not specify in the questionnaire (n = 3). $ No data found in medical records (n = 275).
Table
Table 4. Relationship between prevention of ADRs by HCPs in relation to severity level by the Numerical Rating Scale and Hartwig’s Severity Assessment Scale.
Table 4. Relationship between prevention of ADRs by HCPs in relation to severity level by the Numerical Rating Scale and Hartwig’s Severity Assessment Scale.
MethodsPrevention by HCPs; N (%)
NRS a by PatientsHartwig b by Pharmacist
Mild
(n = 101)		Moderate to Severe
(n = 318)		Total
(n = 419)		p-Value cMild
(n = 220)		Moderate to Severe
(n = 199)		Total
(n = 419)		p-Value c
Medical record/
computer popup		43 (42.6)171 (53.8)214 (51.1)0.05597 (44.1)117 (58.8)214 (51.1)0.003 *
Give allergy card33 (32.7)140 (44.0)173 (41.3)0.044 *66 (30.0)107 (53.8)173 (41.3)<0.001 *
Attach sticker to medical record12 (11.9)43 (13.5)55 (13.1)0.67121 (9.5)34 (17.1)55 (13.1)0.022 *
a NRS: Numerical Rating Scale: mild (0–3), moderate (4–6), and severe (7–10). b Hartwig: Hartwig’s Severity Assessment Scale: mild (1–2), moderate (3–4), and severe (5–7). c Pearson’s chi-squared test, * the level of significant difference <0.05.
Table
Table 5. Top three most commonly reported ADRs and suspected drugs in patients with severe ADRs (rated by NRS a) in relation to management and prevention by patients and HCPs.
Table 5. Top three most commonly reported ADRs and suspected drugs in patients with severe ADRs (rated by NRS a) in relation to management and prevention by patients and HCPs.
Methods% of Patients
ADR SymptomsSuspected Dugs
Management of ADRs by patients (n = 153)
Drug withdrawal
(n = 60, 39.2%)		Rash (46.7%), angioedema (10.0%), dyspnea (5.0%) Penicillin (15.0%), cotrimoxazole (8.3%), diclofenac (6.7%)
Continue drug (same dose)
(n = 16, 10.5%)		Rash (25.0%), dry cough (18.8%), nausea (12.5%)Enalapril (18.8%), amoxicillin and clavulanic acid (6.3%), amlodipine (6.3%)
Use another drug for treating ADRs
(n = 1, 0.7%)		Ankle edema (100.0%)Amlodipine (100.0%)
Consult community pharmacist
(n = 4, 2.6%)		Rash (75.0%), nausea (25.0%)Amoxicillin and clavulanic acid (25.0%), amoxicillin (25.0%), penicillin (25.0%)
Searching for more information
(n = 7, 4.6%)		Angioedema (14.3), dry cough (14.3%), dyspnea (14.3%)Carboplatin (14.3%), diclofenac (14.3%), enalapril (14.3%)
Immediate physician consult
(n = 112, 73.2%)		Rash (53.6%), angioedema (8.0%), dyspnea (8.0%)Penicillin (15.2%), cotrimoxazole (7.1%), amoxicillin (5.4%)
Management of ADRs by HCPs (n = 153)
Drug withdrawal
(n = 53, 34.6%)		Rash (45.3%), dry cough (11.3%), myositis (9.4%)Enalapril (11.3%, cotrimoxazole (7.5%), atorvastatin (5.7%)
Continue drug (decrease dose)
(n = 4, 2.6)		Ankle edema (25.0%), face edema (25.0%), bleeding (25.0%)Amlodipine (25.0%), prednisolone (25.0%), warfarin (25.0%)
Continue drug (same dose)
(n = 5, 3.3%)		Headache (20.0%), hoarseness (20.0%), mucositis (20.0%)Carboplatin (20.0%), levofloxacin (20.0%), seretide accuhaler® (20.0%)
Change to alternative drug
(n = 18, 11.8%)		Dry cough (33.3%), myositis (27.8%), rash (22.2%)Enalapril (33.3%), atorvastatin (11.1%), methimazole (11.1%)
Giving another drug for treating ADRs (n = 18, 11.8%)Rash (77.8%), angioedema (5.6%), dyspnea (5.6%)Ultravist® (16.7%), amoxicillin (11.1%), celecoxib (5.6%)
Prevention of ADRs by patients (n = 147)
Carry of allergy card
(n = 95, 64.6%)		Rash (55.8%), dyspnea (11.6%), angioedema (7.4%)Penicillin (13.7%), cotrimoxazole (7.4%), amoxicillin (5.3%)
Prevention of ADRs by HCPs (n = 153)
Medical record/computer popup
(n = 81, 52.9%)		Rash (54.3%), dyspnea (9.9%), angioedema (8.6%)Penicillin (13.6%), amoxicillin (6.2%), cotrimoxazole (6.2%)
Give allergy card (n = 69, 45.1%)Rash (52.2%), dyspnea (11.6%), angioedema (5.8%)Penicillin (10.1), diclofenac (7.2%), cotrimoxazole (5.8%)
Attach sticker to medical record
(n = 25, 16.3%)		Rash (76.0%), angioedema (8.0%), dyspnea (8.0%)Penicillin (16.0%), celecoxib (8.0%), cotrimoxazole (8.0%)
a NRS: Numerical Rating Scale: mild (0–3), moderate (4–6), and severe (7–10).
Table
Table 6. Multiple logistic regression of factors related to severity levels of ADR symptoms reported by patients.
Table 6. Multiple logistic regression of factors related to severity levels of ADR symptoms reported by patients.
ADR Severity Level Were Rated by Numerical Rating Scale (NRS)
Variables aN (%)Adjusted OR95% CIp-Value
Mild
(n = 101)		Moderate to Severe
(n = 318)		LowerUpper
Sex
 Male51 (50.5)90 (28.3)1 0.088
 Female50 (49.5)228 (71.7)1.6140.9322.795
Age (years)
 18–4415 (14.9)51 (16.0)1
 5–6022 (21.8)103 (32.4)1.9750.8274.7150.125
 >6064 (63.4)164 (51.6)1.2760.5922.7500.534
Bothersome
 Low57 (56.4)85 (26.7)1
 Medium13 (12.9)86 (27.0)3.6782.0296.666<0.001 *
 High4 (4.0)132 (41.5)26.2119.07775.683<0.001 *
ADR Severity Level Were Rated by the Hartwig’s Severity Assessment Scale
Variable bN (%)Adjusted OR95% CIp-Value
Mild
(n = 101)		Moderate to Severe
(n = 318)		LowerUpper
Sex
 Male83 (37.7)58 (29.1)1
 Female137 (62.3)141 (70.9)1.2110.7711.9040.406
Age (years)
 18–4429 (13.2)37 (18.6)1
 5–6070 (31.8)55 (27.6)0.6080.3201.1530.127
 >60121 (55.0)107 (53.8)0.8120.4491.4690.491
Duration of ADRs
 <1–24 h64 (30.6)80 (40.8)1
 1–3 day59 (28.2)53 (27.0)0.6030.3571.0200.059
 4 day–4 weeks63 (30.1)46 (23.5)0.4410.2560.7580.003 *
 >1 month23 (11.0)17 (8.7)0.3880.1800.8340.015 *
Bothersome
 Low121 (55.0)63 (31.7)1
 Medium49 (22.3)50 (25.1)2.3001.3593.8920.002 *
 High50 (22.7)86 (43.2)3.9512.3726.581<0.001 *
a Variables included in the multiple logistic regression analysis were sex, age, and bothersome ADRs. b Variables included in the multiple logistic regression analysis were sex, age, duration of ADRs, and bothersome ADRs. * the level of significant difference <0.05.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Srisuriyachanchai, W.; Cox, A.R.; Kampichit, S.; Jarernsiripornkul, N. Severity and Management of Adverse Drug Reactions Reported by Patients and Healthcare Professionals: A Cross-Sectional Survey. Int. J. Environ. Res. Public Health 2023, 20, 3725. https://doi.org/10.3390/ijerph20043725

AMA Style

Srisuriyachanchai W, Cox AR, Kampichit S, Jarernsiripornkul N. Severity and Management of Adverse Drug Reactions Reported by Patients and Healthcare Professionals: A Cross-Sectional Survey. International Journal of Environmental Research and Public Health. 2023; 20(4):3725. https://doi.org/10.3390/ijerph20043725

Chicago/Turabian Style

Srisuriyachanchai, Warisara, Anthony R. Cox, Sirinya Kampichit, and Narumol Jarernsiripornkul. 2023. "Severity and Management of Adverse Drug Reactions Reported by Patients and Healthcare Professionals: A Cross-Sectional Survey" International Journal of Environmental Research and Public Health 20, no. 4: 3725. https://doi.org/10.3390/ijerph20043725

APA Style

Srisuriyachanchai, W., Cox, A. R., Kampichit, S., & Jarernsiripornkul, N. (2023). Severity and Management of Adverse Drug Reactions Reported by Patients and Healthcare Professionals: A Cross-Sectional Survey. International Journal of Environmental Research and Public Health, 20(4), 3725. https://doi.org/10.3390/ijerph20043725

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop